Hypertrophic Cardiomyopathy

Aficamten Tops Metoprolol in Obstructive HCM as Mavacamten Misses in Nonobstructive Trial

The findings position myosin inhibition to challenge beta-blockers as first-line care pending FDA review of aficamten.